When to use Signatera™ MRD test?
Neoadjuvant Setting
- To assess response to neoadjuvant therapy to help inform next steps
Adjuvant Setting
- Use after surgery to evaluate the need for adjuvant chemotherapy and inform when to escalate or right-size treatment
Surveillance Setting
- Detect MRD with greater sensitivity than current standard of care tools
- Signatera™ is meant to be used serially to detect relapse earlier
![Signatera-high-sensitivity-high-specificity Signatera high sensitivity and specificity](https://www.natera.com/wp-content/uploads/2021/02/Signatera-high-sensitivity-high-specificity.png)
“Detecting relapse before it becomes clinically symptomatic requires a test with high sensitivity and specificity. Signatera™ enables us to confidently identify patients with molecular relapse when the disease burden is so low that it is undetectable with imaging.”
![Lajos Pusztai, MD, DPhil](/wp-content/uploads/2021/01/lajos-pustai-image.png)
Lajos Pusztai, MD, DPhil
Professor of Medicine (Medical Oncology); Co-Leader, Genetics, Genomics and Epigenetics Research Program, Yale Cancer Center, Yale School of Medicine
Not all MRD assays are created equal
Considerations when choosing patient monitoring tools:
![Comprehensive](/wp-content/uploads/2024/07/SGN_WEB_CRC_Icon_1_20240708_NAT-1168.png)
![Demonstrated](/wp-content/uploads/2024/07/SGN_WEB_CRC_Icon_2_20240708_NAT-1168.png)
![Personalized](/wp-content/uploads/2024/07/SGN_WEB_CRC_Icon_3_20240708_NAT-1168.png)
![Validated](/wp-content/uploads/2024/07/SGN_WEB_CRC_Icon_4_20240708_NAT-1168.png)
Extensively validated
Signatera™ has been validated in >65 peer-reviewed publications studying >6,500 patients across >25 tumor types1-6
![Experience](/wp-content/uploads/2024/07/SGN_WEB_CRC_Icon_5_20240708_NAT-1168.png)
Deep experience
Signatera™ has been used to manage over 200,000 patients and has been ordered by more than 1/3 of US oncologists6
Covered by Medicare for multiple solid tumor indications
![Icon 1](/wp-content/uploads/2024/07/SGN_WEB_MRD_Test_Icon_1_20240708_NAT-1168.png)
Stage II-IV and oligometastatic colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings
![Icon 2](/wp-content/uploads/2024/07/SGN_WEB_MRD_Test_Icon_2_20240708_NAT-1168.png)
Stage II-IV breast cancer in the neoadjuvant setting, regardless of subtype
Stage IIb and higher breast cancer in the adjuvant and recurrence monitoring settings
![Icon 3](/wp-content/uploads/2024/07/SGN_WEB_MRD_Test_Icon_3_20240708_NAT-1168.png)
Muscle invasive bladder cancer (MIBC) in the adjuvant and recurrence monitoring settings
![Icon 4](/wp-content/uploads/2024/07/SGN_WEB_MRD_Test_Icon_4_20240708_NAT-1168.png)
Stage II-IV ovarian, fallopian tube, or primary peritoneal cancer in the adjuvant and recurrence monitoring settings
![Icon 5](/wp-content/uploads/2024/07/SGN_WEB_MRD_Test_Icon_5_20240708_NAT-1168.png)
For monitoring of responce to immune-checkpoint inhibitor (ICI) therapy for patients with any solid tumor
Is Signatera™ right for your patients?
We’re here to help you find out
References
1Reinert T, Henriksen TV, Christensen E, et al. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.0528.
2Coombes RC, et al., Clin Cancer Res, 2019.
3Lebow, et al., Front. Oncol, 2023.
4Christensen E, et al. J Clin Oncol, 2019.
5Kotani D. et al, Nature Medicine, 2023.
6Data on file